ANI Pharmaceuticals, Inc. (ANIP)

NASDAQ: ANIP · IEX Real-Time Price · USD
41.97 0.04 (0.10%)
Jan 19, 2022 9:41 AM EST - Market open
Market Cap699.68M
Revenue (ttm)212.46M
Net Income (ttm)-22.10M
Shares Out16.67M
EPS (ttm)-1.83
PE Ration/a
Forward PE9.10
Dividendn/a
Ex-Dividend Daten/a
Volume1,272
Open42.44
Previous Close41.93
Day's Range41.68 - 42.44
52-Week Range26.10 - 60.23
Beta1.21
AnalystsBuy
Price Target61.67 (+46.9%)
Earnings DateNov 4, 2021

About ANIP

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, ...

IndustryPharmaceuticals
Founded2001
CEOPatrick Walsh
Employees369
Stock ExchangeNASDAQ
Ticker SymbolANIP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ANIP stock is "Buy." The 12-month stock price forecast is 61.67, which is an increase of 46.93% from the latest price.

Price Target
$61.67
(46.93% upside)
Analyst Consensus: Buy

News

ANI Pharmaceuticals to Present at the H.C. Wainwright Bioconnect Virtual Conference

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, ...

2 weeks ago - Business Wire

Best Momentum Stocks to Buy for January 3rd

SRTS, ANIP, and AZO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2022

Other symbols:AZOSRTS
2 weeks ago - Zacks Investment Research

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the A...

4 weeks ago - Business Wire

7 of the Best Small-Cap Stocks to Buy Before 2022

With 2021 coming to a close and a new year upon us, it's time to get a head start on some of the best small-cap stocks to buy. The post 7 of the Best Small-Cap Stocks to Buy Before 2022 appeared first o...

1 month ago - InvestorPlace

ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of G...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately...

1 month ago - Business Wire

ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

1 month ago - Business Wire

ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order i...

2 months ago - Business Wire

ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000...

2 months ago - Business Wire

ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI” or the "Company") today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock...

2 months ago - Business Wire

ANI Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of...

2 months ago - Business Wire

ANI Pharmaceuticals reports 3rd Quarter financial results as shares surges

ANI Pharmaceuticals (NASDAQ: ANIP) recently announced that it recorded $52.1 million net revenues for its third quarter of 2021. However, this was roughly one million dollars less than what they reporte...

2 months ago - Invezz

Here's Why Ani Pharmaceuticals Stock Is Rocketing Higher Today

The company reported positive third-quarter earnings, and the FDA granted approval for its generic version of Acthar Gel.

2 months ago - The Motley Fool

ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates

ANI (ANIP) delivered earnings and revenue surprises of 42.25% and 3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports Third Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three months ended September 30, 2021. T...

2 months ago - Business Wire

ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sc...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental N...

2 months ago - Business Wire

ANI Pharmaceuticals to Discuss Third Quarter 2021 Financial Results on November 1, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2021 financial results on Monday, Nove...

2 months ago - Business Wire

Analysts Estimate ANI Pharmaceuticals (ANIP) to Report a Decline in Earnings: What to Look Out for

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

7 Overbought Stocks to Be Very Careful of Right Now

While the market rally this year has been incredible, worrying developments suggest investors should watch out for overbought stocks. The post 7 Overbought Stocks to Be Very Careful of Right Now appeare...

Other symbols:AAWWACYCARCFCHHPBCT
3 months ago - InvestorPlace

ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Offic...

3 months ago - Business Wire

ANI Pharmaceuticals Announces Launch of Nebivolol Tablets

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. ANI's Nebivolol Table...

4 months ago - Business Wire

ANI Pharma's Purified Cortrophin Gel Application Under FDA Review

The FDA has accepted ANI Pharmaceuticals Inc's (NASDAQ: ANIP) supplemental marketing application for Purified Cortrophin Gel. The application seeks approval for multiple indications, including multiple ...

4 months ago - Benzinga

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multip...

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP) today announced that the Company's supplemental New Drug Application (“sNDA”) for Purified Cortrophin® ...

4 months ago - Business Wire

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates

ANI (ANIP) delivered earnings and revenue surprises of 3.08% and 1.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

ANI Pharmaceuticals Reports Second Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, ...

5 months ago - Business Wire

ANI Pharmaceuticals to Discuss Second Quarter 2021 Financial Results on August 6, 2021

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2021 financial results on Friday, Aug...

5 months ago - Business Wire